With 'compelling' effect size, Eli Lilly's Jaypirca advances a step closer to first-line use in CLL

8th September 2025 Uncategorised 0

By nailing the primary endpoint in a phase 3 trial, Eli Lilly’s Bruton tyrosine kinase (BTK) inhibitor Jaypirca has come one step closer to reaching a broader group of patients with blood cancer.

More: With 'compelling' effect size, Eli Lilly's Jaypirca advances a step closer to first-line use in CLL
Source: fierce